寰宇娛樂文化(01046.HK)中期由虧轉盈約5.2萬港元
格隆匯2月28日丨寰宇娛樂文化(01046.HK)公吿,截至2023年12月31日止六個月期間,集團錄得收益約296.4百萬港元(上個期間:約36.3百萬港元)及溢利約52,000港元(上個期間:虧損約28.0百萬港元)。
集團本期間業績較上個期間有所改善,主要由於:(i)於本期間內,錄像發行、電影發行及放映、授出及轉授電影版權業務分部的收益及貢獻大幅增加。於本期間內,隨着新型冠狀病毒疫情於中國及香港的影響逐漸消退,集團於本期間的新電影放映收入較上個期間大幅增加;及(ii)於本期間內,由於人民幣升值,集團於本期間錄得匯兑收益約2.9百萬港元,而集團於上個期間則錄得匯兑虧損約6.3百萬港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.